A groundbreaking international study has found that imlunestrant plus abemaciclib significantly improved progression-free survival (PFS) versus imlunestrant monotherapy in patients with estrogen ...
The DDL Conference, taking place in Edinburgh, Scotland, attracts over 1,000 global experts annually, including scientists, clinicians, and industry leaders. Belhaven Biopharma will present these ...